Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts
- Approximately 86,000 vertebral fragility fractures occur annually in the UK, with most remaining undiagnosed.
- Nanox.AI has signed an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution, with minimum annual license commitments built into the deal.
- A separate optimization project with Intel demonstrates a path for Nanox.AI’s imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud.
A CT scan ordered to answer one clinical question may capture additional anatomical information beyond the original indication. In certain cases, routine CT imaging can include information related to the spine, coronary arteries, liver and other areas, creating an opportunity to support clinical evaluation of findings that may otherwise go unnoticed.
Vertebral fragility fractures illustrate that opportunity. The National Osteoporosis Guideline Group estimates that approximately 549,000 new fragility fractures occur annually in the UK, including roughly 86,000 vertebral fractures. NICE has also stated that most vertebral fragility fractures remain undiagnosed, highlighting the potential value of identifying these findings from scans that have already been performed.
Nano-X Imaging Ltd. (NASDAQ: NNOX) is targeting that gap through Nanox.AI, its medical imaging analytics subsidiary. Two announcements this month advance the same strategy from different directions: one expands the commercial pathway for its bone-health software, while the other addresses how its AI can be deployed within healthcare infrastructure.
Clinical Value from Scans Already Performed
Nanox.AI solutions analyze routine medical CT scans to help identify patients with findings correlated with chronic conditions in areas including cardiac, liver and bone health. Nanox.AI bone solution (“HealthOST”) is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans.
HealthOST is an AI-enabled image processing software that provides qualitative and quantitative analysis of the spine from CT images to support clinicians in the evaluation and assessment of musculoskeletal disease of the spine, such as osteoporosis. The software provides vertebral labeling, vertebral height-loss measurements and vertebral bone-attenuation measurements.
Because eligible CT scans analyzed by HealthOST are performed for other clinical indications, no additional imaging, radiation or patient time is required, enabling opportunistic assessment from routine CT scans. HealthOST is integrated with existing picture archiving and communication systems (“PACS”) and can support timely and appropriate preventive care.
A UK Channel for the Bone Solution
On August 18, Nanox.AI entered a reseller agreement with Vertec Scientific Ltd., granting the company an exclusive license to market and resell HealthOST in the United Kingdom for an initial three-year term, subject to minimum annual license commitments.
Vertec is a UK-based provider of DXA and bone-health solutions, serving hospitals, clinics and healthcare providers across the UK. First established in Berkshire in 1979, Vertec has built nearly five decades of experience as one of the UK’s leading DXA suppliers, supported by nationwide, OEM-authorized engineering coverage and a team of clinically trained applications and product specialists. Its established presence in the bone-health market may provide a specialized commercial channel for HealthOST in the UK.
In November 2025, the National Institute for Health and Care Excellence (“NICE”) included HealthOST, as well as HealthVCF, among five AI technologies recommended as options to aid the opportunistic detection of vertebral fragility fractures in the NHS while further evidence is generated.
Moving Inference Inside the Hospital
Nanox.AI’s second August announcement addressed another potential adoption consideration: where AI processing takes place.
The company optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel’s OpenVINO toolkit. The optimized framework ran inference on Intel Core Ultra-class hardware using OpenVINO, demonstrating its suitability for on-premise AI processing in medical imaging environments.
For healthcare organizations, this type of deployment may support local inference at the edge, help reduce dependence on cloud connectivity and enable deployment models aligned with hospital infrastructure requirements.
Nanox.AI’s technology has also been featured in Intel’s published partner resources as an example of a solution built with Intel technology.
Building the AI Business
Nanox.AI is one component of Nanox’s broader integrated, end-to-end medical imaging and healthcare services platform, which includes Nanox.ARC, Nanox.CLOUD, Nanox.MARKETPLACE, USARAD Holdings and Nanox Health IT.
Nanox generated $4.2 million in revenue in the second quarter of 2026, compared with $3.0 million in the second quarter of 2025. AI and Software Solutions contributed $1.0 million in revenue during the quarter, including $0.9 million generated by Nanox Health IT.
In its September 2026 business update, the company cited continued commercial and clinical momentum for Nanox.AI, including the Vertec Scientific reseller agreement and five new pilot programs
Against that backdrop, the two August developments are relevant to Nanox.AI’s commercial and deployment strategy. The Vertec agreement provides a specialized channel for HealthOST in the UK, while the Intel work demonstrates an approach for running Nanox.AI technology within healthcare environments.
Together, the developments reflect Nanox.AI’s focus on helping healthcare organizations derive additional clinical value from scans that have already been performed.
For more information, visit the company’s website at https://www.nanox.vision.
NOTE TO INVESTORS: The latest news and updates relating to NNOX are available in the company’s newsroom at https://nnw.fm/NNOX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Approximately 86,000 vertebral fragility fractures occur annually in the UK, with most remaining undiagnosed.
- Nanox.AI has signed an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution, with minimum annual license commitments built into the deal.
- A separate optimization project with Intel demonstrates a path for Nanox.AI’s imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud.
A CT scan ordered to answer one clinical question may capture additional anatomical information beyond the original indication. In certain cases, routine CT imaging can include information related to the spine, coronary arteries, liver and other areas, creating an opportunity to support clinical evaluation of findings that may otherwise go unnoticed.
Vertebral fragility fractures illustrate that opportunity. The National Osteoporosis Guideline Group estimates that approximately 549,000 new fragility fractures occur annually in the UK, including roughly 86,000 vertebral fractures. NICE has also stated that most vertebral fragility fractures remain undiagnosed, highlighting the potential value of identifying these findings from scans that have already been performed.
Nano-X Imaging Ltd. (NASDAQ: NNOX) is targeting that gap through Nanox.AI, its medical imaging analytics subsidiary. Two announcements this month advance the same strategy from different directions: one expands the commercial pathway for its bone-health software, while the other addresses how its AI can be deployed within healthcare infrastructure.
Clinical Value from Scans Already Performed
Nanox.AI solutions analyze routine medical CT scans to help identify patients with findings correlated with chronic conditions in areas including cardiac, liver and bone health. Nanox.AI bone solution (“HealthOST”) is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans.
HealthOST is an AI-enabled image processing software that provides qualitative and quantitative analysis of the spine from CT images to support clinicians in the evaluation and assessment of musculoskeletal disease of the spine, such as osteoporosis. The software provides vertebral labeling, vertebral height-loss measurements and vertebral bone-attenuation measurements.
Because eligible CT scans analyzed by HealthOST are performed for other clinical indications, no additional imaging, radiation or patient time is required, enabling opportunistic assessment from routine CT scans. HealthOST is integrated with existing picture archiving and communication systems (“PACS”) and can support timely and appropriate preventive care.
A UK Channel for the Bone Solution
On August 18, Nanox.AI entered a reseller agreement with Vertec Scientific Ltd., granting the company an exclusive license to market and resell HealthOST in the United Kingdom for an initial three-year term, subject to minimum annual license commitments.
Vertec is a UK-based provider of DXA and bone-health solutions, serving hospitals, clinics and healthcare providers across the UK. First established in Berkshire in 1979, Vertec has built nearly five decades of experience as one of the UK’s leading DXA suppliers, supported by nationwide, OEM-authorized engineering coverage and a team of clinically trained applications and product specialists. Its established presence in the bone-health market may provide a specialized commercial channel for HealthOST in the UK.
In November 2025, the National Institute for Health and Care Excellence (“NICE”) included HealthOST, as well as HealthVCF, among five AI technologies recommended as options to aid the opportunistic detection of vertebral fragility fractures in the NHS while further evidence is generated.
Moving Inference Inside the Hospital
Nanox.AI’s second August announcement addressed another potential adoption consideration: where AI processing takes place.
The company optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel’s OpenVINO toolkit. The optimized framework ran inference on Intel Core Ultra-class hardware using OpenVINO, demonstrating its suitability for on-premise AI processing in medical imaging environments.
For healthcare organizations, this type of deployment may support local inference at the edge, help reduce dependence on cloud connectivity and enable deployment models aligned with hospital infrastructure requirements.
Nanox.AI’s technology has also been featured in Intel’s published partner resources as an example of a solution built with Intel technology.
Building the AI Business
Nanox.AI is one component of Nanox’s broader integrated, end-to-end medical imaging and healthcare services platform, which includes Nanox.ARC, Nanox.CLOUD, Nanox.MARKETPLACE, USARAD Holdings and Nanox Health IT.
Nanox generated $4.2 million in revenue in the second quarter of 2026, compared with $3.0 million in the second quarter of 2025. AI and Software Solutions contributed $1.0 million in revenue during the quarter, including $0.9 million generated by Nanox Health IT.
In its September 2026 business update, the company cited continued commercial and clinical momentum for Nanox.AI, including the Vertec Scientific reseller agreement and five new pilot programs
Against that backdrop, the two August developments are relevant to Nanox.AI’s commercial and deployment strategy. The Vertec agreement provides a specialized channel for HealthOST in the UK, while the Intel work demonstrates an approach for running Nanox.AI technology within healthcare environments.
Together, the developments reflect Nanox.AI’s focus on helping healthcare organizations derive additional clinical value from scans that have already been performed.
For more information, visit the company’s website at https://www.nanox.vision.
NOTE TO INVESTORS: The latest news and updates relating to NNOX are available in the company’s newsroom at https://nnw.fm/NNOX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
